Tag Archives: Novartis

Awaiting FDA nod, Novartis touts latest data on gene therapy Zolgensma

As Novartis waits for FDA action on its gene therapy Zolgensma, expected this month, the company has rolled out yet another round of data on the spinal muscular atrophy treatment. Novartis’ AveXis, which developed the gene therapy, touted interim data through March 8 from a phase 1 study in Type 2 SMA patients, plus later-stage… Read More »

Novartis’ Cosentyx beats J&J, Lilly to land first-in-class Chinese psoriasis nod

Novartis’ psoriasis blockbuster Cosentyx has beaten out rivals from Eli Lilly and Johnson & Johnson as the first interleukin inhibitor approved in China. China’s National Medical Product Administration has approved Cosentyx to treat moderate-to-severe plaque psoriasis in adult patients, Novartis said Tuesday. The nod comes months after the Center for Drug Evaluation put Cosentyx among… Read More »

Novartis snags blockbuster OK for secondary progressive multiple sclerosis drug Mayzent

Novartis officially has an approval for Mayzent to treat patients with secondary progressive multiple sclerosis. The next challenge? Getting doctors to diagnose it. The FDA green-lighted the product Tuesday, making it the first-ever oral drug for SPMS and the first new treatment specifically approved for the condition more than 15 years. Regulators based their decision… Read More »